Characteristics of patients studied for single-KIR 2DL3+ NK cells
| UPN no. . | 10 . | 18 . | 54 . | 3 . | 16 . | 17 . | 55 . |
|---|---|---|---|---|---|---|---|
| Predicted NK alloreactivity | yes | yes | yes | no | no | no | no |
| KIR 2DL3 ligand status, don/pat | +/− | +/− | +/− | +/+ | −/+ | +/+ | −/− |
| Diagnosis | AML | ALL | AML | AML | AML | AML | MDS |
| Status at transplantation | CR1 | CR2 | CR2 | Ref/per | Rel | CR1 | CR1 |
| Graft composition | |||||||
| CD34+ cell dose, ×106/kg | 7.0 | 19.5 | 12.1 | 9.2 | 12.3 | 10.9 | 10.3 |
| CD3+ cell dose, ×104/kg | 0.4 | 0.8 | 1.2 | 0.3 | 1.0 | 1.2 | 1.1 |
| Day of KIR2DL3-single positive NK-cell analysis | 156 | 105 | 86 | 151 | 75 | 97 | 115 |
| No. of T-cell add-backs received at analysis | 1 | 2 | 1 | 2 | 2 | 1 | 1 |
| Day of T-cell add-backs | 98 | 43, 72 | 34 | 104, 143 | 37, 75 | 47 | 34 |
| Total T-cell add-back dose received at analysis | 10 | 11 | 0.1 | 11 | 11 | 1 | 1 |
| Disease status at analysis | CR | CR | CR | Relapse | CR | CR | CR |
| UPN no. . | 10 . | 18 . | 54 . | 3 . | 16 . | 17 . | 55 . |
|---|---|---|---|---|---|---|---|
| Predicted NK alloreactivity | yes | yes | yes | no | no | no | no |
| KIR 2DL3 ligand status, don/pat | +/− | +/− | +/− | +/+ | −/+ | +/+ | −/− |
| Diagnosis | AML | ALL | AML | AML | AML | AML | MDS |
| Status at transplantation | CR1 | CR2 | CR2 | Ref/per | Rel | CR1 | CR1 |
| Graft composition | |||||||
| CD34+ cell dose, ×106/kg | 7.0 | 19.5 | 12.1 | 9.2 | 12.3 | 10.9 | 10.3 |
| CD3+ cell dose, ×104/kg | 0.4 | 0.8 | 1.2 | 0.3 | 1.0 | 1.2 | 1.1 |
| Day of KIR2DL3-single positive NK-cell analysis | 156 | 105 | 86 | 151 | 75 | 97 | 115 |
| No. of T-cell add-backs received at analysis | 1 | 2 | 1 | 2 | 2 | 1 | 1 |
| Day of T-cell add-backs | 98 | 43, 72 | 34 | 104, 143 | 37, 75 | 47 | 34 |
| Total T-cell add-back dose received at analysis | 10 | 11 | 0.1 | 11 | 11 | 1 | 1 |
| Disease status at analysis | CR | CR | CR | Relapse | CR | CR | CR |
At analysis, no patient had GVHD or was on immunosuppressive therapy.